In short
- This measurement says nothing about recovery and resistance: people with a progressive condition of the motor nerve cells had about a fifth more of the immune signal TNFR-1 in their spinal fluid than a control group, in a small measurement of 45 patients and 30 control subjects.1
- The level told the two groups apart reasonably well but far from perfectly, and the authors write that the finding shows neither a reliable way to tell people apart nor cause and effect.1
- Signalling through TNFR1 can lead to either survival or cell death, depending on the circumstances, so a higher level of this signal does not on its own tell you whether it does harm or good.2
Contents
- What one immune signal says, and why it says nothing about recovery and resistance
- Living longer, and more news about what happens in your body
- How the immune system sends messages, and where knowledge ran out
- A new measurement from Szczecin
- What the team measured, and in whom
- A signpost, not a verdict
- What the finding did not show
- In short, and what you can do now
- Frequently asked questions
What one immune signal says, and why it says nothing about recovery and resistance
In this piece you will read what one raised immune signal in spinal fluid can tell you, and why it says nothing about your own body’s recovery and resistance. It is based on a new finding: people with a serious, progressive condition of the motor nerve cells had more of one immune signal in the fluid around their brain and spinal cord than people without that condition. That matters, because headlines about markers in blood and body fluids reach you more and more often, and if you know the difference between a signal in a group and a verdict on one person, you can read those headlines calmly.

Verified by Carlos Mendoza Montano
Doctorate in nutritional biochemistry from the University of Arizona
Reviewed on 29 October 2026
You come home after a long day. Over dinner you scroll past a headline saying that some value in the blood, or in the fluid around the nerves, points to a serious condition. You wonder what a value like that means, and whether one measured number could say anything about you. The headline doesn’t tell you how to read it, and you are left with a vague worry and no idea what to do with it.
Living longer, and more news about what happens in your body

In 2026, Statistics Netherlands (CBS) reported that life expectancy at birth in the Netherlands in 2025 was 83.5 years for women and 80.7 years for men.3 In Germany, the federal statistics office Destatis reported in 2026 that life expectancy at birth in 2025 stood at 83.6 years for women and 79.1 years for men.4
However your own years turn out, headlines about what happens in the body will keep reaching you. You are one of many people who want to know what a headline like that means for them.
Separately from this research, the recovery scan gives you a first picture of where you stand with your recovery today. The scan has no connection with the marker in this piece. The scan is not a diagnosis: it gives you self-insight, but it says nothing about any condition.
How the immune system sends messages, and where the knowledge stopped
The immune system works with messengers: small proteins that cells release to warn other cells that something needs attention. TNF-alpha is one of those messengers in the innate immune system, the body’s fast first line of defence. A messenger only has an effect once it docks onto a receptor, a kind of lock on a cell. TNF-alpha has two such receptors, called TNFR1 and TNFR2. The outer part of each can also break away from the cell and end up in body fluid; in that soluble form it can still bind TNF-alpha and can stop TNF-alpha from acting on cells.2 It is this soluble form of the first receptor, written as TNFR-1, that can be measured in the spinal fluid.
For years, researchers have been looking at these messengers in a progressive condition of the motor neurons, the nerve cells that control your muscles; it is a condition a doctor names. A 2021 review brought together earlier work that found raised levels of TNF-alpha and both receptors in blood plasma, serum, spinal fluid and nerve tissue, in patients and in animal models.2 Work in Australia looked beyond the brain and spinal cord: in the blood of 48 patients and 23 people without the condition, the share of two kinds of white blood cells, monocytes and neutrophils, was about the same in both groups. What differed was the balance between two types of monocytes, classical and non-classical: a more severe condition went together with fewer non-classical monocytes, and a marker on neutrophils, CD16, was linked to how severe the condition was and how quickly it progressed.5
Yet the knowledge stopped just short of the step that matters most to anyone reading a headline. A systematic review with meta-analysis of markers in blood and spinal fluid found neurofilament light chain to be the best-supported marker so far, yet still not accurate enough on its own; markers of immune signals turned out to be of limited clinical value.6 The review article on TNF-alpha described the mechanism as still disputed: signalling through TNFR1 can trigger both survival signals and cell death signals in a cell, depending on the circumstances, and opinions remain divided on whether TNF-alpha protects motor nerve cells or harms them.2 So it remained unclear how immune signals in the blood relate to those in spinal fluid, and whether a raised level points to damage, to defence, or to nothing at all.
A new measurement from Szczecin
The new finding comes from eight researchers at the Pomeranian Medical University in Szczecin, Poland, in the Department of Neurology and the Department of General Pathology. The first author is A. Wełnicka-Wesołowska of the Department of Neurology; the other authors are K. Łuczkowska, P. Nowacki, E. Paczkowska, A. Meller, K. Machowska-Sempruch, B. Machaliński and M. Gołąb-Janowska.1 The article appeared on 17 October 2026 in Neurological Sciences, the official journal of the Italian Neurological Society and the Italian Society of Clinical Neurophysiology. It is a journal article, not a preprint, and the authors themselves call it an exploratory cross-sectional study of an association: a look at a single moment in time.
Why would a measurement in people with a serious nerve condition matter to you? Because it shows, in one clear case, how a marker is read. The team asked exactly the question behind the headline on your phone: does an immune signal in body fluid differ between people with a condition and people without it, and does a value in the blood tell the same story as a value in spinal fluid? The researchers’ answer, and the limits the researchers themselves place on it, give you a way to read any news about markers.
What the team measured, and in whom

The group was small: 45 people with the sporadic form of the condition and 30 people in a control group, each measured once.1 In the blood, the team looked at CRP, a general alarm protein of the immune system, at the blood count and at fibrinogen. In the spinal fluid, the team measured TNF-alpha, the receptor TNFR-1 and CRP, alongside clinical features.1 The full paper tells you who these people were. The patients were 27 to 65 years old, 53.8 on average, because they came from a clinical trial that took no one over 65. The control participants were 30 people who had been seen at the neurology emergency department for headache, with no sign of a long-term nerve condition, 23 to 78 years old, 47.3 on average. The two groups differed significantly in age.1
The clearest result: the patients had clearly more TNFR-1 in their spinal fluid than the control group, about a fifth more on average.1 That difference held after the authors took age and sex into account.1 In an exploratory analysis, the TNFR-1 level told patients apart from control participants fairly well, but far from perfectly. TNFR-1 also rose slightly with age. Links with how severe the condition was, and a lower level in people whose first symptoms began in the muscles for speaking and swallowing, were exploratory and not firm.1
CRP told a different story. It did not differ between the groups, but the level in the blood and the level in the spinal fluid rose closely together, in patients just as much as in control participants.1 That link is not specific to the condition.1
A signpost, not a verdict
The one idea you can take from this piece is the difference between a signal that differs between groups and a signal that tells you something about one person. A marker can genuinely be higher in a group of patients and still be a poor guide for each individual, because the values of the two groups overlap.
Picture a basketball team and a group of people waiting at a bus stop. On average the players are clearly taller, and height separates the two groups reasonably well. Still, if you see one tall person at the bus stop, it is unwise to conclude that this person plays basketball: many tall people never play, and some players are of ordinary height. That is roughly what “reasonably well but far from perfectly” means for TNFR-1.1 A group average says something true about groups; it does not sort individuals.
A smoke alarm in your kitchen goes off when the house is on fire, and also when you burn the toast. The sound tells you that something is going on, but not what. Here, CRP behaved like that kind of general alarm: the levels in the blood and the spinal fluid rose together in patients and in control participants, so the link said nothing specific about the condition.1 Many immune signals work this way, which fits the wider finding that markers of immune signalling have so far proved to be of limited clinical value.6
Behind the first two questions lies another one: when a signal is higher, is it doing harm, or is it the body defending itself? For TNFR-1, that question is open. The 2021 review describes signalling through TNFR1 that, depending on the circumstances, can lead to survival or to cell death, and the soluble receptor in body fluid can bind TNF-alpha and stop it from acting on cells.2 A higher TNFR-1 level may be part of an immune response, a trace of damage or a bystander, and this measurement cannot show which of those it is.
Work from Stockholm points the same way for immune molecules inside the nervous system. Molecules called HLA and beta-2 microglobulin changed in vulnerable motor nerve cells, but removing beta-2 microglobulin in mice preserved only some of the connections between nerve and muscle and did not extend survival: such molecules seem to influence how vulnerable the cells are, without being major drivers.7 The first author of that separate work put it like this:
The findings suggest that vulnerable motor neurons actively try to counter disease-related stress, but that this response is ultimately insufficient.
Melanie Leboeuf, first author of the study, researcher, Stockholm University8
Cells can set off a response that is real and measurable, and still not enough. That is a reminder that a raised immune signal can be the trace of an effort rather than the cause of a problem.
So why measure signals like these at all, if they cannot sort individuals? Because differences between groups can still help decide where to look next and who to include in future research. The lead author of the Australian work on blood cells made the link to the people who take part in studies:
Our findings could help in selecting patients for these studies, which could lead to better outcomes.
Trent Woodruff, professor, School of Biomedical Sciences, lead author, The University of Queensland9
Note the cautious words: “could help”, “could lead”. A candidate marker earns its place step by step, and the Polish authors are just as cautious about TNFR-1: in their words, a candidate marker worth further research.1
What the finding did not show
The authors set out the limits themselves, and they are worth reading calmly. The measurement was taken once, in 75 people, so it cannot show how TNFR-1 changes over time. There was no comparison group of people with other nerve conditions, so the finding cannot say whether the raised level belongs to this condition in particular. The barrier between blood and spinal fluid was not measured, so the finding cannot say how much of what was found in the spinal fluid came over from the blood. The patients were also older than the control participants; the authors took age into account, but write that some influence of age cannot be ruled out, and that a patient group aged 65 at most limits how far the result applies to everyone with the condition. The authors write that their findings show neither that the measurement can reliably tell patients apart from others, nor cause and effect, and they call for studies that follow people over time, with comparison groups of people with other nerve conditions and with measurements of that barrier.1
The measurement also did not look at recovery in healthy people, at lifestyle or at anything you can change yourself. The study describes a difference between two small groups at a single moment, nothing more.
In short, and what you can do now

In short: immune messengers such as TNF-alpha work through receptors, and earlier work found raised levels of these signals in a progressive disease of the motor nerve cells.2 The new measurement from Szczecin found about a fifth more TNFR-1 in the spinal fluid of 45 patients than in that of 30 control participants, a difference that held after adjusting for age and sex, while CRP did not differ between the groups, and its levels in blood and spinal fluid rose together across both groups combined.1 The level separated the groups reasonably well but far from perfectly; it was measured once, in a small group, and it shows neither a reliable way to tell people apart nor cause and effect.1 A higher level of this signal does not, on its own, say whether it does harm or good.2
Three directions follow from this, and none of them is a prescription. First, read news about markers with three questions: who was it measured in, who were they compared with, and can the value tell one person apart from another? Second: if a change in your body worries you or does not go away, a doctor is the one who can look for the cause; a headline cannot. Third, keep a single study in proportion: an exploratory measurement in a small group of patients is a starting point for further research. Recovery after exercise is a separate topic; you can read what sleep, protein and alcohol do to it in a separate article on poor recovery after exercise.
If, separately from this research, you want a picture of where you stand today with recovery and resistance, the recovery scan below gives you a first picture, as self-insight. The scan is not a diagnosis.
Frequently asked questions
What is TNFR-1?
A receptor for the immune messenger TNF-alpha. Its outer part can break away into body fluid such as the spinal fluid, where it can still bind TNF-alpha and stop TNF-alpha from acting on cells; the new study measured this soluble form. A 2021 review described signalling through TNFR1 that, depending on the circumstances, can lead to survival or to cell death, and called the mechanism still disputed.2
Can a value in spinal fluid tell whether someone has this disease?
Not on the basis of this finding. TNFR-1 separated 45 patients from 30 control participants reasonably well, but far from perfectly, and the authors write that their results do not show that the measurement can reliably tell patients apart from others.1 Of all the markers in blood and spinal fluid examined so far, even the best supported one is not accurate enough on its own.6 Whether someone has a disease is for a doctor to determine.
Does a raised CRP in my blood say anything about my nerves?
This finding gives no reason to think so. CRP in the blood and in the spinal fluid did not differ between patients and control participants, and in both groups the two levels rose and fell closely together, a link that is not specific to the condition.1 Questions about your own values belong with your doctor.
Do immune signals cause the disease?
That has not been shown. The Polish authors write that their findings do not show cause and effect.1 In mice, removing one immune molecule, beta2-microglobulin, preserved only some of the connections between nerve and muscle and did not extend survival: molecules like this seem to influence vulnerability without being major drivers.7
Sources
Every source below was checked on the day this article was published. The numbering follows the text.
- Wełnicka-Wesołowska A, Łuczkowska K, Nowacki P, Paczkowska E, Meller A, Machowska-Sempruch K, Machaliński B, Gołąb-Janowska M. Neurological Sciences 47(11), 2026. PMID 42891860. doi.org/10.1007/s10072-026-09480-9
- Guidotti G, Scarlata C, Brambilla L, Rossi D. Cells, 2021. doi.org/10.3390/cells10030518
- CBS. 173 duizend mensen overleden in 2025. 2026. cbs.nl
- Destatis. Lebenserwartung bei Geburt für Frauen und Männer im Jahr 2025 auf neue Höchstwerte gestiegen. Press release, 2026. destatis.de
- McGill RB, Steyn FJ, Ngo ST, Thorpe KA, Heggie S, Ruitenberg MJ, Henderson RD, McCombe PA, Woodruff TM. Brain Communications, 2020. doi.org/10.1093/braincomms/fcaa013
- Obara K, Ito D, Nilsson C, Janelidze S, Santillo A, Katsuno M, Mattsson-Carlgren N. European Journal of Neurology, 2025. doi.org/10.1111/ene.70382
- Leboeuf M, Nijssen J, Comley LH, Aguila Benitez JC, Mei I, Gómez Alcalde S, Muñoz de Bustillo-Alfaro RA, Radoi V, Nichterwitz S, Schweingruber C, Acevedo Arozena A, Hedlund E, Cullheim S. Acta Neuropathologica 151(1), 2026. doi.org/10.1007/s00401-026-03024-3
- Melanie Leboeuf, first author of the study, Stockholm University. Press release on the study in Acta Neuropathologica. Newswise, 2026. newswise.com
- Trent Woodruff, professor, School of Biomedical Sciences, The University of Queensland. UQ News, 2020. news.uq.edu.au
Quotations from English have been translated by BioProfile.
Also read
See where you stand with your recovery
Answer the questions in the recovery scan and see where you stand today with recovery and resilience. The scan is not a diagnosis: it gives you insight into yourself.
Free, about 3 minutes. An analysis of your answers, never a diagnosis.
BioProfile analyses your health status to guide you and your coach. It does not make a diagnosis, only a doctor can do that. Built on validated health questionnaires; the combined BioProfile score is not itself a validated clinical instrument yet. Your answers stay private (GDPR).
